Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Animal Models

Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98–HOXA9-induced myeloid disease

Leukemia volume 29, pages 2086–2097 (2015)Cite this article

Subjects

Abstract

Acute myeloid leukemia (AML) occurs when multiple genetic aberrations alter white blood cell development, leading to hyperproliferation and arrest of cell differentiation. Pertinent animal models link in vitro studies with the use of new agents in clinical trials. We generated a transgenic zebrafish expressing human NUP98–HOXA9 (NHA9), a fusion oncogene found in high-risk AML. Embryos developed a preleukemic state with anemia and myeloid cell expansion, and adult fish developed a myeloproliferative neoplasm (MPN). We leveraged this model to show that NHA9 increases the number of hematopoietic stem cells, and that oncogenic function of NHA9 depends on downstream activation of meis1, the PTGS/COX pathway and genome hypermethylation through the DNA methyltransferase, dnmt1. We restored normal hematopoiesis in NHA9 embryos with knockdown of meis1 or dnmt1, as well as pharmacologic treatment with DNA (cytosine-5)-methyltransferase (DNMT) inhibitors or cyclo-oxygenase (COX) inhibitors. DNMT inhibitors reduced genome methylation to near normal levels. Strikingly, we discovered synergy when we combined sub-monotherapeutic doses of a histone deacetylase inhibitor plus either a DNMT inhibitor or COX inhibitor to block the effects of NHA9 on zebrafish blood development. Our work proposes novel drug targets in NHA9-induced myeloid disease, and suggests rational therapies by combining minimal doses of known bioactive compounds.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Burnett A, Wetzler M, Löwenberg B . Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487–494.

    Article  PubMed  Google Scholar 

  2. Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL . Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev 2004; 30: 103–117.

    Article  PubMed  Google Scholar 

  3. Borthakur G, Estey EE . Therapy of acute myelogenous leukemia in adults. Nagarajan L. Acute Myelogenous Leukemia: Genetics, Biology and Therapy. Springer New York: New York City, NY, USA, 2010 pp 257–270.

    Google Scholar 

  4. Gilliland DG, Tallman MS . Focus on acute leukemias. Cancer Cell 2002; 1: 417–420.

    Article  CAS  PubMed  Google Scholar 

  5. Argiropoulos B, Humphries RK . Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007; 26: 6766–6776.

    Article  CAS  PubMed  Google Scholar 

  6. Borrow J, Shearman AA, Stanton VP, Becher R, Collins T, Williams AJ et al. The t(7;11)(p15;p15) translocation in acute myeloid leukmaemia fuses the genes for nucleoporin NUP98 and class 1 homeoprotein HOXA9. Nat Genet 1996; 12: 159–167.

    Article  CAS  PubMed  Google Scholar 

  7. Lawrence HJ, Rozenfeld S, Cruz C, Matsukuma K, Kwong A, Kömüves L et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 1999; 13: 1993–1999.

    Article  CAS  PubMed  Google Scholar 

  8. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP . Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531–537.

    Article  CAS  PubMed  Google Scholar 

  9. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjian HM . Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2002, 73–110.

    Article  Google Scholar 

  10. Calvo KR, Knoepfler PS, Sykes DB, Pasillas MP, Kamps MP . Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia. Proc Natl Acad Sci USA 2001; 98: 13120–13125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009; 113: 2375–2385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ohno Y, Yasunaga S, Janmohamed S, Ohtsubo M, Saeki K, Kurogi T et al. Hoxa9 transduction induces hematopoietic stem and progenitor cell activity through direct down-regulation of geminin protein. PLoS One 2013; 8: e53161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Calvo KR, Sykes DB, Pasillas MP, Kamps MP . Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene 2002; 21: 4247–4256.

    Article  CAS  PubMed  Google Scholar 

  14. Hatano Y, Miura I, Nakamura T, Yamazaki Y, Takahashi N, Miura AB . Molecular heterogeneity of the NUP98/HOXA9 fusion transcript in myelodysplastic syndromes associated with t(7;11)(p15;p15). Br J Haematol 1999; 107: 600–604.

    Article  CAS  PubMed  Google Scholar 

  15. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G . Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998; 17: 3714–3725.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G . NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J 2001; 20: 350–361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Langenau DM, Traver D, Ferrando AA, Kutok JL, Aster JC, Kanki JP et al. Myc-induced T cell leukemia in transgenic zebrafish. Science 2003; 299: 887–890.

    Article  CAS  PubMed  Google Scholar 

  18. Sabaawy HE, Azuma M, Embree LJ, Tsai H-J, Starost MF, Hickstein DD . TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006; 103: 15166–15171.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Streisinger G, Walker C, Dower N, Knauber D, Singer F . Production of clones of homozygous diploid zebra fish (Brachydanio rerio). Nature 1981; 291: 293–296.

    Article  CAS  PubMed  Google Scholar 

  20. Yeh J-RJ, Munson KM, Elagib KE, Goldfarb AN, Sweetser DA, Peterson RT . Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol 2009; 5: 236–243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Forrester AM, Grabher C, McBride ER, Boyd ER, Vigerstad MH, Edgar A et al. NUP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis. Br J Haematol 2011; 155: 167–181.

    Article  PubMed  Google Scholar 

  22. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007; 447: 1007–1011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Goessling W, Allen RS, Guan X, Jin P, Uchida N, Dovey M et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011; 8: 445–458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650–1653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Westerfield M . The zebrafish book. A Guide For The Laboratory Use of Zebrafish (Danio rerio). 4th edn University of Oregon Press: Eugene, Oregon, 2000.

    Google Scholar 

  26. Kissa K, Herbomel P . Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 2010; 464: 112–115.

    Article  CAS  PubMed  Google Scholar 

  27. Lin H-F, Traver D, Zhu H, Dooley K, Paw BH, Zon LI et al. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood 2005; 106: 3803–3810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lam EYN, Chau JYM, Kalev-Zylinska ML, Fountaine TM, Mead RS, Hall CJ et al. Zebrafish runx1 promoter-EGFP transgenics mark discrete sites of definitive blood progenitors. Blood 2009; 113: 1241–1249.

    Article  CAS  PubMed  Google Scholar 

  29. Bennett CM, Kanki JP, Rhodes J, Liu TX, Paw BH, Kieran MW et al. Myelopoiesis in the zebrafish, Danio rerio. Blood 2001; 98: 643–651.

    Article  CAS  PubMed  Google Scholar 

  30. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CaJ, Van Putten WLJ, Valk PJM, Delwel R . Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088–3091.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Network TCGAR. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia The Cancer Genome Atlas Research Network. N Engl J Med 2013; 368: 2059–2074.

    Article  Google Scholar 

  32. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G . Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia. Mol Cell Biol 2001; 21: 224–234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cvejic A, Serbanovic-Canic J, Stemple DL, Ouwehand WH . The role of meis1 in primitive and definitive hematopoiesis during zebrafish development. Haematologica 2011; 96: 190–198.

    Article  PubMed  Google Scholar 

  34. Yeh J-RJ, Munson KM, Chao YL, Peterson QP, Macrae CA, Peterson RT . AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 2008; 135: 401–410.

    Article  CAS  PubMed  Google Scholar 

  35. Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M et al. P53-independent, normal stem cell sparing epigenetic-differentation therapy for myeloid and other malignancies. Semin Oncol 2012; 39: 97–108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29: 2889–2896.

    Article  CAS  PubMed  Google Scholar 

  37. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH . Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 2012; 26: 344–349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Tittle RK, Sze R, Ng A, Nuckels RJ, Swartz ME, Anderson RM et al. Uhrf1 and Dnmt1 are required for development and maintenance of the zebrafish lens. Dev Biol 2011; 350: 50–63.

    Article  CAS  PubMed  Google Scholar 

  39. Chu J, Loughlin Ea, Gaur Na, SenBanerjee S, Jacob V, Monson C et al. UHRF1 phosphorylation by cyclin A2/cyclin-dependent kinase 2 is required for zebrafish embryogenesis. Mol Biol Cell 2011; 23: 59–70.

    Article  PubMed  Google Scholar 

  40. Arita K, Ariyoshi M, Tochio H, Nakamura Y, Shirakawa M . Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism.pdf. Nature 2008; 455: 818–821.

    Article  CAS  PubMed  Google Scholar 

  41. Bostick M, Kim JK, Estève PO, Clark A, Pradhan S, Jacobsen SE . UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007; 317: 1760–1764.

    Article  CAS  PubMed  Google Scholar 

  42. Ceccaldi A, Rajavelu A, Champion C, Rampon C, Jurkowska R, Jankevicius G et al. C5-DNA Methyltransferase Inhibitors: From Screening to Effects on Zebrafish Embryo Development. ChemBioChem 2011; 12: 1337–1345.

    Article  CAS  PubMed  Google Scholar 

  43. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E . Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 2009; 30: 55–60.

    Article  CAS  PubMed  Google Scholar 

  44. Bellos F, Mahlknecht U . Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008; 31: 629–633.

    CAS  PubMed  Google Scholar 

  45. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969–6978.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Marks P, Rifkind Ra, Richon VM, Breslow R, Miller T, Kelly WK . Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194–202.

    Article  CAS  PubMed  Google Scholar 

  47. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T . DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000; 24: 88–91.

    Article  CAS  PubMed  Google Scholar 

  48. Savickiene J, Treigyte G, Borutinskaite V-V, Navakauskiene R . Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells. Cell Mol Biol Lett 2012; 17: 501–525.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Wiltse J . Mode of Action: Inhibition of Histone Deacetylase, Altering WNT-Dependent Gene Expression, and Regulation of Beta-Catenin—Developmental Effects of Valproic Acid. Crit Rev Toxicol 2005; 35: 727–738.

    Article  CAS  PubMed  Google Scholar 

  50. Lord AM, North TE, Zon LI . Prostaglandin E2: Making more of your bone marrow. Cell Cycle 2007; 6: 3054–3057.

    Article  CAS  PubMed  Google Scholar 

  51. Iwasaki M, Kuwata T, Yamazaki Y, Jenkins Na, Copeland NG, Osato M et al. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model. Blood 2005; 105: 784–793.

    Article  CAS  PubMed  Google Scholar 

  52. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL . Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009; 136: 1136–1147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Arand J, Spieler D, Karius T, Branco MR, Meilinger D, Meissner A et al. In vivo Control of CpG and Non-CpG DNA Methylation by DNA Methyltransferases. PLoS Genet 2012; 8: e1002750.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G . Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 2014; 26: 577–590.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.

    Article  CAS  PubMed  Google Scholar 

  56. Saba HI . Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007; 3: 807–817.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Maslov a Y, Lee M, Gundry M, Gravina S, Strogonova N, Tazearslan C et al. 5-aza-2’-deoxycytidine-induced genome rearrangements are mediated by DNMT1. Oncogene 2012; 31: 5172–5179.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25: 3884–3891.

    Article  CAS  PubMed  Google Scholar 

  59. Detich N, Bovenzi V, Szyf M . Valproate induces replication-independent active DNA demethylation. J Biol Chem 2003; 278: 27586–27592.

    Article  CAS  PubMed  Google Scholar 

  60. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25–42.

    Article  CAS  PubMed  Google Scholar 

  61. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogeden A et al. All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia. N Engl J Med 1997; 337: 1021–1028.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Angela Young, Jessica Hill and Emma Cummings for zebrafish care and maintenance; Jocelyn Jaques for administrative support. This work is supported by a Canadian Institutes of Health Research /Nova Scotia Health Research Foundation Regional Partnership Program Grant MED-Matching 2011–7509 (CIHR#.243778). APD is funded by The Cancer Research Training Program, supported by The Terry Fox Strategic Health Research Training Program in Cancer Research by the Beatrice Hunter Cancer Research Institute. AMF is funded by a Canadian Institutes of Health Research Banting and Best Graduate Student Award. The MeDIP work is supported by the MeDIP-seq Program Project Grant funded by Terry Fox Foundation (TFF-122869) to MH. JNB is supported by a Cancer Care Nova Scotia Peggy Davison Clinician Scientist Award.

Author contributions

APD and AMF conceived and conducted experiments, analyzed the data and wrote the paper. AJC and GSW conducted experiments and analyzed the data. CG generated the original NUP98-HOXA9 transgenic zebrafish line. ICC and DL performed microarray experiments and analyzed microarray data. MM performed MeDIP studies and analyzed methylation data. GA conducted human AML gene data set analysis. VR generated associated microarray figures. RL performed cytospins and cell morphological analysis. MH oversaw MeDIP studies and analysis and edited the manuscript. SML oversaw microarray studies and analysis and edited the manuscript. KS oversaw human AML gene data set analysis. ATL oversaw development of original NUP98–HOXA9-transgenic line and edited the manuscript. JNB conceived experiments, oversaw all the zebrafish studies, wrote and edited the manuscript.

Author information

Author notes

  1. A P Deveau and A M Forrester: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada

    A P Deveau, A M Forrester, V Rajan, S M Lewis & J N Berman

  2. Department of Pediatrics, IWK Health Centre, Halifax, Nova Scotia, Canada

    A P Deveau, A M Forrester, A J Coombs, G S Wagner, V Rajan & J N Berman

  3. Department of Marine Biology, Dalhousie University, Halifax, Nova Scotia, Canada

    A J Coombs & G S Wagner

  4. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    C Grabher, G Alexe, K Stegmaier & A T Look

  5. Institute of Toxicology & Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany

    C Grabher

  6. Department of Biology, University of New Brunswick, Saint John, New Brunswick, Canada

    I C Chute, D Léger & S M Lewis

  7. Department of Microbiology & Immunology, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia, Canada

    M Mingay & M Hirst

  8. Harvard Medical School, Boston, MA, USA

    G Alexe & K Stegmaier

  9. Department of Pathology, Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada

    R Liwski

  10. Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada

    R Liwski & J N Berman

  11. Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada

    M Hirst

  12. Department of Chemistry & Biochemistry, Université de Moncton, Moncton, New Brunswick, Canada

    S M Lewis

  13. Atlantic Cancer Research Institute, Moncton, New Brunswick, Canada

    S M Lewis

  14. Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada

    J N Berman

Authors
  1. A P Deveau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A M Forrester
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A J Coombs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G S Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Grabher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I C Chute
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Léger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Mingay
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Alexe
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V Rajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R Liwski
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Hirst
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. K Stegmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S M Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A T Look
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J N Berman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J N Berman.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deveau, A., Forrester, A., Coombs, A. et al. Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98–HOXA9-induced myeloid disease. Leukemia 29, 2086–2097 (2015). https://doi.org/10.1038/leu.2015.126

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.126

This article is cited by

Search

Advanced search

Quick links